… is an established option for second-line treatment of patients with advanced NSCLC [1., 2.,
3.]. Treatment with erlotinib produces significant survival benefits in a broad patient …

… A phase 3 clinical trial compared erlotinib alone with erlotinib plus bevacizumab in patients
… In that trial, patients were not enrolled based on EGFR mutation status. Overall survival (OS) …

… From the medical record, we obtained the information regarding erlotinib or gefitinib
delivery, disease status, and survival. This review of records was done under a waiver of …

… regarding the association of smoking status with overall survival (OS) and progression-free
survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. …

… stratified all patients according to different lines of gefitinib or erlotinib. The disparities of
choices on gefitinib or erlotinib (more male, non-adenocarcinoma and smokers using erlotinib) …

… Post-study treatments may confound the true effect of first-line treatment on OS. In the
current study, ∼40% of erlotinib-treated patients in the overall population and exon 19 deletion …

… effect on OS of firstline therapy with gefitinib or erlotinib as first-generation EGFR-TKI vs
chemotherapy in patients with … individual patient data from RCTs with updated survival outcomes. …

… -TKIs), such as gefitinib and erlotinib, has revolutionized the … showed erlotinib to be
effective in advanced NSCLC patients … by the Tarceva Lung Cancer Survival Treatment (TRUST) …

… a concentration-driven drug effect model described erlotinib effect. An activating epidermal
growth factor receptor (EGFR) mutation increased the drug effect as assessed using FDG-…

… experienced progression-free survival a median of 7.8 … patients who experienced 204
events randomized to receive gemcitabine plus erlotinib experienced progression-free survival a …